𝛼SK or SearchD. Western Therapeutics Institute (DWTI) (4576 JP) - Q4 Follow-Up - March 3, 2026
SUMMARY
- The summary of full-year results for D. Western Therapeutics Institute (abbreviated as “DWTI,” hereinafter the “Company”) for FY2025/12 is as follows.
- Net sales fell 17.8% YoY to JPY 387 mn, mainly reflecting the end of domestic single-agent royalty income from glaucoma treatment drug GLANATEC® in September 2024.
- In terms of expenses, cost of sales came to JPY 38 mn (-17.0% YoY), while SG&A expenses dropped 40.7% YoY to JPY 968 mn. Of the SG&A expenses, R&D expenses came to JPY 669 mn (-51.0% YoY).
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- D. Western Therapeutics Institute (DWTI) (4576 JP) - Q4 Follow-Up - March 3, 202612 Mar 2026
x